RVTYHealthcare · Diagnostics & ResearchThe 17 Wall Street analysts covering Revvity, Inc. hold a median 12-month price target of $122 — +5.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 1 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Revvity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (90): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Growth (53): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (13): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own Revvity, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on RVTY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +5.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $110 → $125 |
| 26 June 2026 | Bernstein | Reinstates | Market Perform | $115 |
| 2 June 2026 | Wolfe Research | Assumes | Peer Perform | — |
| 7 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 6 May 2026 | JP Morgan | Maintains | Neutral | — |
| 6 May 2026 | Stifel | Maintains | Hold | — |
| 6 May 2026 | TD Cowen | Maintains | Buy | — |
| 4 May 2026 | Baird | Maintains | Outperform | — |
| 14 Apr 2026 | Barclays | Downgrade | Equal-Weight | — |
| 14 Apr 2026 | Goldman Sachs | Maintains | Neutral | — |
| 31 Mar 2026 | JP Morgan | Maintains | Neutral | — |
| 3 Feb 2026 | Barclays | Maintains | Overweight | — |
| 3 Feb 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 3 Feb 2026 | Jefferies | Maintains | Hold | — |
| 3 Feb 2026 | JP Morgan | Maintains | Neutral | — |
| 3 Feb 2026 | TD Cowen | Maintains | Buy | — |
| 3 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 15 Dec 2025 | Barclays | Maintains | Overweight | — |
| 15 Dec 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 9 Dec 2025 | Goldman Sachs | Initiates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 14% of US stocks
Cheaper than 29% of US stocks
Cheaper than 50% of US stocks
Cheaper than 19% of US stocks
Higher than 47% of US stocks
Higher than 32% of US stocks
Higher than 69% of US stocks
Higher than 70% of US stocks
Higher than 67% of US stocks
Higher than 50% of US stocks
Higher than 61% of US stocks
Higher than 4% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RVTY appears on the weeks it earns a place.
Revvity's Board of Directors declared a regular quarterly dividend of $0.07 per share of common stock, payable on November 13, 2026 to shareholders of record as of October 23, 2026.
Why it matters — The declaration of a regular quarterly dividend signals the company's continued commitment to returning capital to shareholders.
Revvity, Inc. (RVTY) is scheduled to report its second-quarter 2026 financial results on August 4, before the market opens, according to Zacks Investment Research.
Why it matters — The upcoming earnings report will provide investors with updated financial performance data and insight into the company's recent operational results.
A Zacks Investment Research report indicates Revvity (RVTY) lacks the right combination of key ingredients for a likely earnings beat in its upcoming report. The article outlines key expectations ahead of next week's release.
Why it matters — The report suggests RVTY may miss earnings expectations, which could affect short-term market perception of the stock.
Revvity (RVTY) is developing the T-SPOT A201, a high-throughput platform for latent TB testing targeting a 2027 launch that promises greater lab efficiency and scalability.
Why it matters — The new platform could expand Revvity's diagnostic offerings in infectious disease testing, potentially opening a new revenue stream if it reaches the commercial market as planned.
The 17 Wall Street analysts covering Revvity, Inc. have a median 12-month price target of $122, with estimates ranging from $90 to $145. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 17 analysts covering Revvity, Inc., 6 rate it a Buy, 11 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Revvity, Inc. 86 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Revvity, Inc. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (90 of 100).
No one can know that. What the data says: the median 12-month target from 17 analysts implies +5.9% from the last close, and Ticker Nerd's factor model ranks Revvity, Inc. 86 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Revvity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RVTY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $90 to $145 over the next 12 months.
Revvity, Inc. returned +31.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Revvity Inc. is a health science tools and diagnostics company that provides end-to-end solutions for research, development, testing, and clinical use.
The most recent item we track (Business Wire, 31 July 2026): "Revvity Board Declares Quarterly Dividend". Revvity's Board of Directors declared a regular quarterly dividend of $0.07 per share of common stock, payable on November 13, 2026 to shareholders of record as of October 23, 2026.
Revvity Inc. is a health science tools and diagnostics company that provides end-to-end solutions for research, development, testing, and clinical use. The company operates through two main segments: Life Sciences and Diagnostics, serving customers across pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and government organizations. Its portfolio includes reagents, consumables, assays, instruments, software, and specialized services that support workflows from discovery through diagnosis. Revvity focuses on areas such as translational multi-omics, biomarker identification, imaging, screening, detection, informatics, reproductive health, immunodiagnostics, and genomic testing. It also supports applications in rare disease testing, newborn screening, hereditary cancer, and broader clinical laboratory services. Based in Waltham, Massachusetts, Revvity plays an important role in the healthcare and life sciences ecosystem by helping researchers, clinicians, and laboratories generate and analyze data across a wide range of scientific and diagnostic applications.
CEO Dr. Prahlad R. Singh Ph.D. · 11,000 employees · United States · https://www.revvity.com